Press releases

• 17/11/2025

  CROSSJECT completes €5 million financing with Vatel Capital

  Read the press release (PDF, new tab)
• 25/09/2025

  CROSSJECT presents its financial results and key highlights for the first half of 2025

  Read the press release (PDF, new tab)
• 22/09/2025

  CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam)

  Read the press release (PDF, new tab)
• 04/08/2025

  CROSSJECT remains engaged during the summer break

  Read the press release (PDF, new tab)
• 01/07/2025

  Notice to holders of warrants issued in December 2024

  Read the press release (PDF, new tab)
• 24/06/2025

  CROSSJECT announces a successful capital increase of €5.7 million

  Read the press release (PDF, new tab)
• 11/06/2025

  CROSSJECT advances on the development of ZEPIZURE® Junior

  Read the press release (PDF, new tab)
• 05/06/2025

  Launch of a capital increase with preferential subscription rights for nearly 5 million euros

  Read the press release (PDF, new tab)
• 03/06/2025

  Maxim Group initiates the coverage of the CROSSJECT share

  Read the press release (PDF, new tab)
• 27/05/2025

  CROSSJECT implements new manufacturing module to scale-up the ZENEO® Factory ‘s versatility and capacity

  Read the press release (PDF, new tab)
• 20/05/2025

  CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval

  Read the press release (PDF, new tab)
• 15/05/2025

  CROSSJECT’s ZENEO® needle-free auto-injector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors

  Read the press release (PDF, new tab)
• 07/05/2025

  CROSSJECT provides updates on the EUA filing of ZEPIZURE®

  Read the press release (PDF, new tab)
• 27/03/2025

  CROSSJECT reports financial results for 2024

  Read the press release (PDF, new tab)
• 25/03/2025

  CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program

  Read the press release (PDF, new tab)
• 19/03/2025

  CROSSJECT achieves key ZEPIZURE® manufacturing batch stability milestones

  Read the press release (PDF, new tab)
• 12/02/2025

  Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board

  Read the press release (PDF, new tab)
• 06/02/2025

  Completion of the transactions announced in December 2024 relating to the amendment of the convertible bonds subscribed by an entity affiliated to Heights Capital Management, inc. (“Heights”) and the issue of a second assimilable tranche

  Read the press release (PDF, new tab)